Teva Pharmaceutical Industries Limited Total Assets
Teva Pharmaceutical Industries Limited total assets. Based on the latest financial reports, Teva Pharmaceutical Industries Limited (TEV) holds total assets worth €40.04 Billion EUR (≈ $46.81 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Teva Pharmaceutical Industries Limited market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Teva Pharmaceutical Industries Limited (2015–2025)
Total assets of Teva Pharmaceutical Industries Limited from 2015 to 2025. This chart illustrates how Teva Pharmaceutical Industries Limited's total assets have evolved over time, based on quarterly financial data. See Teva Pharmaceutical Industries Limited stock price for real-time trading data and today's change.
Teva Pharmaceutical Industries Limited - Asset Composition Analysis
Teva Pharmaceutical Industries Limited Total Assets Breakdown (December 2025)
Teva Pharmaceutical Industries Limited total assets breakdown as of December 2025. Teva Pharmaceutical Industries Limited's total assets of €40.04 Billion consist of 34.2% current assets and 65.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.7% |
| Accounts Receivable | €3.71 Billion | 9.1% |
| Inventory | €3.18 Billion | 7.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €3.78 Billion | 9.3% |
| Goodwill | €16.00 Billion | 39.3% |
Asset Composition Trend (2015–2025)
This chart illustrates how Teva Pharmaceutical Industries Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TEV current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Teva Pharmaceutical Industries Limited's current assets represent 34.2% of total assets in 2025, an increase from 33.9% in 2015.
- Cash Position: Cash and equivalents constituted 8.7% of total assets in 2025, down from 12.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, a decrease from 49.0% in 2015.
- Asset Diversification: The largest asset category is goodwill at 39.3% of total assets.
Teva Pharmaceutical Industries Limited Competitors by Total Assets
Key competitors of Teva Pharmaceutical Industries Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Teva Pharmaceutical Industries Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.01 | 1.03 | 1.01 |
| Quick Ratio | 0.78 | 0.74 | 0.67 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €178.00 Million | €371.00 Million | €131.00 Million |
Teva Pharmaceutical Industries Limited - Advanced Valuation Insights
This section examines the relationship between Teva Pharmaceutical Industries Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.08 |
| Latest Market Cap to Assets Ratio | 0.85 |
| Asset Growth Rate (YoY) | 3.6% |
| Total Assets | €40.75 Billion |
| Market Capitalization | $34.58 Billion USD |
Valuation Analysis
Near Book Valuation: The market values Teva Pharmaceutical Industries Limited's assets close to their book value (0.85x), suggesting investors view the company's assets at approximately fair value.
Positive Asset Growth: Teva Pharmaceutical Industries Limited's assets grew by 3.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Teva Pharmaceutical Industries Limited (2015–2025)
The table below shows the annual total assets of Teva Pharmaceutical Industries Limited from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €40.75 Billion ≈ $47.64 Billion |
+3.62% |
| 2024-12-31 | €39.33 Billion ≈ $45.98 Billion |
-9.55% |
| 2023-12-31 | €43.48 Billion ≈ $50.83 Billion |
-1.20% |
| 2022-12-31 | €44.01 Billion ≈ $51.45 Billion |
-7.68% |
| 2021-12-31 | €47.67 Billion ≈ $55.73 Billion |
-5.87% |
| 2020-12-31 | €50.64 Billion ≈ $59.20 Billion |
-11.88% |
| 2019-12-31 | €57.47 Billion ≈ $67.19 Billion |
-5.29% |
| 2018-12-31 | €60.68 Billion ≈ $70.94 Billion |
-14.07% |
| 2017-12-31 | €70.61 Billion ≈ $82.56 Billion |
-23.98% |
| 2016-12-31 | €92.89 Billion ≈ $108.60 Billion |
+71.28% |
| 2015-12-31 | €54.23 Billion ≈ $63.40 Billion |
-- |
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-po… Read more